Mereo BioPharma Group plc Banner Image

Mereo BioPharma Group plc

  • Ticker MREO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Mereo BioPharma Group plc Logo Image
  • 11-50 Employees
  • Based in London, England
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab ("Anti-TIGIT"), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b studyMore in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI"), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD") and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
4.7 / 5.0 (96)

Mereo BioPharma Group plc reports have an aggregate usefulness score of 4.7 based on 96 reviews.

Mereo BioPharma Group plc

Most Recent Annual Report

Mereo BioPharma Group plc
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Mereo BioPharma Group plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!